



## SASKATCHEWAN FORMULARY BULLETIN

### Update to the 62nd Edition of the Saskatchewan Formulary

| <b>Product</b> | <b>DIN</b> | <b>Pre-Markup (\$)</b> |
|----------------|------------|------------------------|
|----------------|------------|------------------------|

**New Non-Interchangeable Full Formulary Listings Effective April 1, 2013:**

|   |          |         |
|---|----------|---------|
| <b>Allerject</b> (epinephrine) (AVT)      |          |         |
| 0.15/0.15mg unidose injection             | 02382059 | 81.0000 |
| 0.3mg/0.3ml unidose injection             | 02382067 | 81.0000 |
| <b>Asmanex</b> (mometasone furoate) (MRK) |          |         |
| 200mcg powder for inhalation              | 02243595 | 35.0000 |
| 400mcg powder for inhalation              | 02243596 | 70.0000 |
| <b>MyGlucoHealth</b> (EHS)                |          |         |
| Blood Glucose Test Strip                  | 97799458 | 0.6854  |

**New Exception Drug Status (EDS) Listings Effective April 1, 2013:**

|  |          |        |
|--|----------|--------|
| <b>Vyvanse</b> (lisdexamfetamine dimesylate) (SCI) |          |        |
| 20mg capsule                                       | 02347156 | 2.5500 |
| 30mg capsule                                       | 02322951 | 3.0500 |
| 40mg capsule                                       | 02347164 | 3.5500 |
| 50mg capsule                                       | 02322978 | 4.0500 |
| 60mg capsule                                       | 02347172 | 4.5500 |

For treatment of persons suffering from attention deficit disorder and in whom:

(a) The use of methylphenidate (short- or long-acting) or of dexamphetamine has not properly controlled the symptoms of the disease.

(b) Cannot swallow tablets/capsules whole, and require a liquid form of long-acting ADHD medication therapy.

|   |          |          |
|---|----------|----------|
| <b>Zenhale</b> (mometasone furoate/formoterol fumarate dihydrate) (MRK) |          |          |
| 50mcg/5mcg inhalation aerosol   | 02361744 | 68.9000  |
| 100mcg/5mcg inhalation aerosol  | 02361752 | 87.4400  |
| 200mcg/5mcg inhalation aerosol  | 02361760 | 105.9800 |

For treatment of asthma in patients uncontrolled on inhaled steroid therapy.

**Additional Formulations of current Exception Drug Status (EDS) Listings Effective April 1, 2013:**

- **nevirapine, extended release tablet, 400mg (Viramune XR-(BOE))**

For management of HIV disease. *This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.*

**Drugs Reviewed and Not Approved for Listing in the Saskatchewan Formulary:**

- **Lodalis, tablet, 625mg (colesevelam hydrochloride) (VAE)**
- **Fampyra, sustained release tablet, 10mg (fampridine) (BGN)**

**Saskatchewan Ministry of Health  
Drug Plan and Extended Benefits Branch  
2<sup>nd</sup> Floor, 3475 Albert Street  
Regina, Saskatchewan S4S 6X6  
(306) 787-3317  
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.